These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

406 related articles for article (PubMed ID: 22925456)

  • 1. Clinical breakpoint changes and their impact on surveillance of antimicrobial resistance in Escherichia coli causing bacteraemia.
    van der Bij AK; van Dijk K; Muilwijk J; Thijsen SF; Notermans DW; de Greeff S; van de Sande-Bruinsma N;
    Clin Microbiol Infect; 2012 Nov; 18(11):E466-72. PubMed ID: 22925456
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of Clinical Laboratory Standards Institute and European Committee on Antimicrobial Susceptibility Testing guidelines for the interpretation of antibiotic susceptibility at a University teaching hospital in Nairobi, Kenya: a cross-sectional study.
    Kassim A; Omuse G; Premji Z; Revathi G
    Ann Clin Microbiol Antimicrob; 2016 Apr; 15():21. PubMed ID: 27068515
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of changes in CLSI and EUCAST breakpoints for susceptibility in bloodstream infections due to extended-spectrum β-lactamase-producing Escherichia coli.
    Rodríguez-Baño J; Picón E; Navarro MD; López-Cerero L; Pascual A;
    Clin Microbiol Infect; 2012 Sep; 18(9):894-900. PubMed ID: 21985560
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of European Committee on Antimicrobial Susceptibility Testing (EUCAST) and CLSI screening parameters for the detection of extended-spectrum β-lactamase production in clinical Enterobacteriaceae isolates.
    Polsfuss S; Bloemberg GV; Giger J; Meyer V; Hombach M
    J Antimicrob Chemother; 2012 Jan; 67(1):159-66. PubMed ID: 21972269
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of clinical breakpoint changes in CLSI guidelines 2010/2011 and EUCAST guidelines 2011 on antibiotic susceptibility test reporting of Gram-negative bacilli.
    Hombach M; Bloemberg GV; Böttger EC
    J Antimicrob Chemother; 2012 Mar; 67(3):622-32. PubMed ID: 22167240
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Consequences of switching from a fixed 2 : 1 ratio of amoxicillin/clavulanate (CLSI) to a fixed concentration of clavulanate (EUCAST) for susceptibility testing of Escherichia coli.
    Leverstein-van Hall MA; Waar K; Muilwijk J; Cohen Stuart J;
    J Antimicrob Chemother; 2013 Nov; 68(11):2636-40. PubMed ID: 23766488
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Assessment of the Phoenix™ automated system and EUCAST breakpoints for antimicrobial susceptibility testing against isolates expressing clinically relevant resistance mechanisms.
    Giani T; Morosini MI; D'Andrea MM; García-Castillo M; Rossolini GM; Cantón R
    Clin Microbiol Infect; 2012 Nov; 18(11):E452-8. PubMed ID: 22909279
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of antimicrobial pharmacokinetic/pharmacodynamic breakpoints with EUCAST and CLSI clinical breakpoints for Gram-positive bacteria.
    Asín E; Isla A; Canut A; Rodríguez Gascón A
    Int J Antimicrob Agents; 2012 Oct; 40(4):313-22. PubMed ID: 22921422
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Contemporary potencies of minocycline and tetracycline HCL tested against Gram-positive pathogens: SENTRY Program results using CLSI and EUCAST breakpoint criteria.
    Jones RN; Wilson ML; Weinstein MP; Stilwell MG; Mendes RE
    Diagn Microbiol Infect Dis; 2013 Apr; 75(4):402-5. PubMed ID: 23514756
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antimicrobial susceptibility of Escherichia coli from community-acquired urinary tract infections in Europe: the ECO·SENS study revisited.
    Kahlmeter G; Poulsen HO
    Int J Antimicrob Agents; 2012 Jan; 39(1):45-51. PubMed ID: 22055529
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [The comparison of antibiotic susceptibilities of uropathogenic Escherichia coli isolates in transition from CLSI to EUCAST].
    Süzük S; Kaşkatepe B; Avcıküçük H; Aksaray S; Başustaoğlu A
    Mikrobiyol Bul; 2015 Oct; 49(4):494-501. PubMed ID: 26649407
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Assessment of the comparability of CLSI, EUCAST and Stokes antimicrobial susceptibility profiles for Escherichia coli uropathogenic isolates.
    O'Halloran C; Walsh N; O'Grady MC; Barry L; Hooton C; Corcoran GD; Lucey B
    Br J Biomed Sci; 2018 Jan; 75(1):24-29. PubMed ID: 29210602
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Trends in antimicrobial susceptibility of Escherichia coli isolates from urology services in The Netherlands (1998-2005).
    Nys S; Terporten PH; Hoogkamp-Korstanje JA; Stobberingh EE;
    J Antimicrob Chemother; 2008 Jul; 62(1):126-32. PubMed ID: 18417487
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The antimicrobial susceptibility of Escherichia coli isolated in eastern area of Romania. A surveillance study.
    Poiată A; Tuchilus C; Bădicut I; Grigore L; Filipiuc S; Adomniţei C; Buiuc D
    Roum Arch Microbiol Immunol; 1999; 58(2):177-84. PubMed ID: 11845455
    [TBL] [Abstract][Full Text] [Related]  

  • 15. MIC of amoxicillin/clavulanate according to CLSI and EUCAST: discrepancies and clinical impact in patients with bloodstream infections due to Enterobacteriaceae.
    Delgado-Valverde M; Valiente-Mendez A; Torres E; Almirante B; Gómez-Zorrilla S; Borrell N; Aller-García AI; Gurgui M; Almela M; Sanz M; Bou G; Martínez-Martínez L; Cantón R; Antonio Lepe J; Causse M; Gutiérrez-Gutiérrez B; Pascual Á; Rodríguez-Baño J;
    J Antimicrob Chemother; 2017 May; 72(5):1478-1487. PubMed ID: 28093484
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical consequences of increased ciprofloxacin and gentamicin resistance in patients with Escherichia coli bacteraemia in the Netherlands.
    Cranendonk DR; van der Valk M; Langenberg ML; van der Meer JT
    Scand J Infect Dis; 2012 May; 44(5):363-8. PubMed ID: 22200089
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Relative performance of antimicrobial susceptibility assays on clinical Escherichia coli isolates from animals.
    Badger S; Abraham S; Saputra S; Trott DJ; Turnidge J; Mitchell T; Caraguel CGB; Jordan D
    Vet Microbiol; 2018 Feb; 214():56-64. PubMed ID: 29408033
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A comparison of E. coli susceptibility for amoxicillin/clavulanic acid according to EUCAST and CLSI guidelines.
    Vanstokstraeten R; Belasri N; Demuyser T; Crombé F; Barbé K; Piérard D
    Eur J Clin Microbiol Infect Dis; 2021 Nov; 40(11):2371-2377. PubMed ID: 34175999
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Contemporary tetracycline susceptibility testing: doxycycline MIC methods and interpretive criteria (CLSI and EUCAST) performance when testing Gram-positive pathogens.
    Jones RN; Stilwell MG; Wilson ML; Mendes RE
    Diagn Microbiol Infect Dis; 2013 May; 76(1):69-72. PubMed ID: 23490012
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of revised CLSI breakpoints for susceptibility to third-generation cephalosporins and carbapenems among Enterobacteriaceae isolates in the Asia-Pacific region: results from the Study for Monitoring Antimicrobial Resistance Trends (SMART), 2002-2010.
    Huang CC; Chen YS; Toh HS; Lee YL; Liu YM; Ho CM; Lu PL; Liu CE; Chen YH; Wang JH; Tang HJ; Yu KW; Liu YC; Chuang YC; Xu Y; Ni Y; Ko WC; Hsueh PR
    Int J Antimicrob Agents; 2012 Jun; 40 Suppl():S4-10. PubMed ID: 22749058
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.